Linking up with Germany’s Neuraxpharm to sell the multiple sclerosis drug Briumvi in Europe and elsewhere has gone down badly with investors but the bashing that TG Therapeutics’ shares has taken seems excessive.

Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.

In light of its ongoing focus on European expansion and a desire to sharpen concentration on its central CNS business, Neuraxpharm has opted to divest its API subsidiary Inke to a private equity firm.